Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia

Published:2014 Issue:6 Volume:29 Page:449-454
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Abumiya Maiko,Takahashi Naoto,Niioka Takenori,Kameoka Yoshihiro,Fujishima Naohito,Tagawa Hiroyuki,Sawada Kenichi,Miura Masatomo

Publisher

Japanese Society for the Study of Xenobiotics

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference22 articles.

1. Nilotinib: a secondgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia;DeRemer;Clin. Ther.,2008

2. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL;Weisberg;Br. J. Cancer,2006

3. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl;Weisberg;Cancer Cell,2005

4. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia;Breccia;Leuk. Res.,2010

5. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL;Kantarjian;N. Engl. J. Med.,2006

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt;Pharmaceuticals;2024-07-03

2. Combination of UGT1A1 polymorphism and baseline plasma bilirubin levels in predicting the risk of antipsychotic-induced dyslipidemia in schizophrenia patients;Schizophrenia;2024-05-17

3. A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer;Clinical and Translational Science;2024-05

4. Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia;Cureus;2024-03-20

5. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3